Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combining antidepressants.

David L Dunner1

  • 1Center for Anxiety and Depression, Mercer Island, Washington, United States.

Shanghai Archives of Psychiatry
|February 3, 2015
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Use of Vagus Nerve Stimulation (VNS) in the Management of Patients with Difficult-to-Treat Major Depressive Disorder (MDD): An Expert Consensus Statement.

Neuropsychiatric disease and treatment·2026
Same author

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.

The international journal of neuropsychopharmacology·2026
Same author

Prognostic and Prescriptive Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report.

The Journal of clinical psychiatry·2025
Same author

Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial.

Brain stimulation·2024
Same author

Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial.

Brain stimulation·2024
Same author

Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.

Brain stimulation·2024
Same journal

Assessing the Accuracy of Diagnostic Tests.

Shanghai archives of psychiatry·2019
Same journal

Hypokalemia Caused by Quetiapine and Risperidone Treatment in Schizophrenia: A Case Report.

Shanghai archives of psychiatry·2019
Same journal

Posterior Fossa Arachnoid Cyst Presenting as Negative Symptoms of Psychosis.

Shanghai archives of psychiatry·2019
Same journal

Research Status and Strategies for Cognitive Function in Schizophrenia.

Shanghai archives of psychiatry·2019
Same journal

The Effect of Repetitive Transcranial Magnetic Stimulation on the Reinstatement of Methamphetamine-Induced Conditioned Place Preference in Rats.

Shanghai archives of psychiatry·2019
Same journal

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia.

Shanghai archives of psychiatry·2019
See all related articles

Treatment-resistant depression presents challenges for psychiatrists. Effective strategies involve medication adjustments, combining antidepressants, or augmenting with non-antidepressant options for better patient outcomes.

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Treatment-resistant depression (TRD) affects a significant patient population.
  • Effective management of TRD remains a clinical challenge for healthcare providers.

Purpose of the Study:

  • To outline current therapeutic strategies for patients with treatment-resistant depression.
  • To provide an overview of medication management approaches for TRD.

Main Methods:

  • Review of established and emerging treatment protocols for TRD.
  • Analysis of pharmacological interventions including monotherapy, polypharmacy, and augmentation.

Main Results:

  • Modifying existing antidepressant medications is a primary approach.
Keywords:
Treatment-resistant depressionantidepressant polypharmacyaugmentationswitching antidepressants

Related Experiment Videos

  • Antidepressant polypharmacy and augmentation with non-antidepressant agents are viable options.
  • Individualized treatment plans are crucial for managing TRD.

    • Conclusions:

    • Multiple pharmacological strategies exist to manage treatment-resistant depression.
    • Optimizing treatment requires careful consideration of medication changes and augmentation.
    • Further research is needed to refine TRD management protocols.